AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20073213 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Chinese and Western medicine (Yuntu recipe)
Number of subjects: 60
Study 20073213 — intervention group
Group type: COMPARATOR
Intervention: Western medical supportive treatment (fluid infusion)
Number of subjects: 60
Study 20073213 — intervention group
Group type: COMPARATOR
Intervention: Normal control (30 women with regular pregnancy)
Number of subjects: 60
Study 17504881 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (ON condition)
Number of subjects: 23
Study 17504881 — intervention group
Group type: COMPARATOR
Intervention: No levodopa (OFF condition)
Number of subjects: 23
Study 17504881 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (OFF condition)
Number of subjects: 23
Study 17504881 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (ON condition)
Number of subjects: 23
Study 15140849 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia program
Number of subjects: 517
Study 11453674 — intervention group
Group type: EXPERIMENTAL
Intervention: Perlite exposure (n=36)
Number of subjects: 58
Study 11453674 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoker perlite workers (n not specified)
Number of subjects: 58
Study 11453674 — intervention group
Group type: COMPARATOR
Intervention: Unexposed office workers (n=22)
Number of subjects: 58
Study 9869784 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA intraocular lens
Number of subjects: 240
Study 9869784 — intervention group
Group type: COMPARATOR
Intervention: Silicone intraocular lens
Number of subjects: 240
Study 9869784 — intervention group
Group type: COMPARATOR
Intervention: Soft acrylic intraocular lens
Number of subjects: 240
Study 8304565 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg pentamidine isethionate, administered in four every-other-day injections
Number of subjects: 89
Study 8304565 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg pentamidine isethionate, administered in four every-other-day injections
Number of subjects: 89
Study 8304565 — intervention group
Group type: COMPARATOR
Intervention: Standard Glucantime therapy
Number of subjects: 89
Study 2720865 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water (group A, 24 patients)
Number of subjects: 49
Study 2720865 — intervention group
Group type: COMPARATOR
Intervention: Glycine 1.5 per cent (group B, 25 patients)
Number of subjects: 49
Study 30547424 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up (1 to 14 days post-discharge)
Number of subjects: 863
Study 30547424 — intervention group
Group type: COMPARATOR
Intervention: Clinical visit after discharge
Number of subjects: 863
Study 30547424 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 863
Study 28765032 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling with oral administration of 0.2 ml of 24% sucrose
Number of subjects: 87
Study 28765032 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling with oral administration of breast milk
Number of subjects: 87
Study 28765032 — intervention group
Group type: COMPARATOR
Intervention: Swaddling with oral administration of distilled water (control)
Number of subjects: 87
Study 26376345 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 30
Study 22965458 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose spinal anaesthesia (8-mg hyperbaric bupivacaine 0.5% with fentanyl 20 μg)
Number of subjects: 40
Study 22965458 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 40
Study 20856124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitch scan mode (HPM)
Number of subjects: 60
Study 20856124 — intervention group
Group type: COMPARATOR
Intervention: Conventional pitch mode (CPM)
Number of subjects: 60
Study 18845966 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (HIET): 9 participants exercised 3 d x wk(-1) at an intensity > lactate threshold (LT) and 2 d x wk(-1) <= LT
Number of subjects: 27
Study 18845966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training (LIET): 11 participants exercised 5 d x wk(-1) at an intensity <= lactate threshold (LT)
Number of subjects: 27
Study 18845966 — intervention group
Group type: COMPARATOR
Intervention: No-exercise training (Control): 7 participants maintained their existing levels of physical activity
Number of subjects: 27
Study 17063068 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced tester (tester 1)
Number of subjects: 43
Study 17063068 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced tester (tester 2)
Number of subjects: 43
Study 17063068 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAP test
Number of subjects: 43
Study 12760315 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient canals presence in hypertensive patients
Number of subjects: 215
Study 12760315 — intervention group
Group type: COMPARATOR
Intervention: Nutrient canals presence in normotensive patients
Number of subjects: 215
Study 9862848 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 0
Study 9862848 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic ligation (EL)
Number of subjects: 0
Study 8554246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy with 3 or more daily insulin injections or continuous subcutaneous insulin infusion, guided by 4 or more glucose tests per day
Number of subjects: 1441
Study 8554246 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with 1 or 2 daily insulin injections
Number of subjects: 1441
Study 1992534 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg/d megestrol acetate
Number of subjects: 55
Study 1992534 — intervention group
Group type: EXPERIMENTAL
Intervention: 960 mg/d megestrol acetate
Number of subjects: 55
Study 1992534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 1992534 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose megestrol acetate
Number of subjects: 55
Study 1992534 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate
Number of subjects: 55
Study 6411382 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 61
Study 6411382 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cromoglycates
Number of subjects: 61
Study 6411382 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide
Number of subjects: 61
Study 6411382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 30630500 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypofractionated (MHF) group (52 patients in Arms 1-3)
Number of subjects: 82
Study 30630500 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme hypofractionated (EHF) group (30 patients in Arms 4-5)
Number of subjects: 82
Study 30630500 — intervention group
Group type: EXPERIMENTAL
Intervention: MHF group (low-risk)
Number of subjects: 82
Study 30630500 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF group (low-risk)
Number of subjects: 82
Study 30630500 — intervention group
Group type: EXPERIMENTAL
Intervention: MHF group (intermediate risk)
Number of subjects: 82
Study 30630500 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF group (intermediate risk)
Number of subjects: 82
Study 30630500 — intervention group
Group type: EXPERIMENTAL
Intervention: MHF group (high risk)
Number of subjects: 82
Study 30630500 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF group (high risk)
Number of subjects: 82
Study 30630500 — intervention group
Group type: EXPERIMENTAL
Intervention: MHF group
Number of subjects: 82
Study 30630500 — intervention group
Group type: COMPARATOR
Intervention: EHF group
Number of subjects: 82
Study 28953501 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 40 μg/kg
Number of subjects: 90
Study 28953501 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 90
Study 28833962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 28833962 — intervention group
Group type: COMPARATOR
Intervention: Folic Acid (FA)
Number of subjects: 0
Study 28833962 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine plus Lamotrigine
Number of subjects: 0
Study 28833962 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine monotherapy
Number of subjects: 0
Study 28833962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26394340 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital workflow process
Number of subjects: 20
Study 26394340 — intervention group
Group type: COMPARATOR
Intervention: Conventional pathway
Number of subjects: 20
Study 23361654 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone ring tourniquet (SRT)
Number of subjects: 50
Study 23361654 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic cuff tourniquet (PT)
Number of subjects: 50
Study 21704307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine dependence (CD) participants during reward anticipation
Number of subjects: 20
Study 21704307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine dependence (CD) participants during reward notification
Number of subjects: 20
Study 21704307 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (HC) participants
Number of subjects: 20
Study 19108741 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-based education and activation
Number of subjects: 444
Study 19108741 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation program 1
Number of subjects: 444
Study 19108741 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation program 2
Number of subjects: 444
Study 16141382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training (80% peak aerobic capacity, T(H))
Number of subjects: 25
Study 16141382 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training (65% peak aerobic capacity, T(M))
Number of subjects: 25
Study 16141382 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity (stretching) placebo control (50% peak aerobic capacity, C(TB))
Number of subjects: 25
Study 16141382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training (T(H))
Number of subjects: 25
Study 14617222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin + NPH insulin
Number of subjects: 60
Study 14617222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin + metformin
Number of subjects: 60
Study 14617222 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin + NPH insulin
Number of subjects: 60
Study 10685722 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg/Indapamide 0.625 mg (Per/Ind)
Number of subjects: 446
Study 10685722 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg (Ate)
Number of subjects: 446
Study 9086133 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day hydroxyurea
Number of subjects: 26
Study 9086133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/day hydroxyurea
Number of subjects: 26
Study 9086133 — intervention group
Group type: COMPARATOR
Intervention: Control (didanosine therapy only)
Number of subjects: 26
Study 7886561 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 0
Study 7886561 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 7886561 — intervention group
Group type: COMPARATOR
Intervention: Blood products usage
Number of subjects: 0
Study 3761959 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol hydrochloride
Number of subjects: 14
Study 3761959 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate
Number of subjects: 14
Study 3761959 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol hydrochloride and Timolol maleate
Number of subjects: 14
Study 30664008 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon‐α (IFN‐α) 9×10 IU/m, n=125
Number of subjects: 250
Study 30664008 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous interleukin-2 (IL‐2) 9×10 IU/m, n=125
Number of subjects: 250
Study 30664008 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous interleukin-2 (IL‐2), n=125
Number of subjects: 250
Study 30664008 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon‐α (IFN‐α), n=125
Number of subjects: 250
Study 30040818 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multifaceted intervention (n = 154) including physiotherapist-led vestibular rehabilitation (35%), internet-based cognitive-behavioral therapy (19%), Otago home-based exercise program (24%), and medical management (40%)
Number of subjects: 305
Study 30040818 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control; n = 151)
Number of subjects: 305
Study 30040818 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multifaceted intervention
Number of subjects: 305
Study 27966509 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil pulling with rice bran oil
Number of subjects: 30
Study 27966509 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil pulling with sesame oil
Number of subjects: 30
Study 27966509 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinsing
Number of subjects: 30
Study 27966509 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all three interventions
Number of subjects: 30
Study 25422085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention aimed at team level, including development of a team specific lifestyle plan and training on creating a healthy environment.
Number of subjects: 0
Study 25422085 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 0
Study 23788468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) with intravenous (IV) fentanyl
Number of subjects: 40
Study 23788468 — intervention group
Group type: COMPARATOR
Intervention: PainBuster (0.5% ropivacaine via a multi‐orifice catheter)
Number of subjects: 40
Study 19995933 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tafenoquine
Number of subjects: 654
Study 19995933 — intervention group
Group type: COMPARATOR
Intervention: 250 mg mefloquine
Number of subjects: 654
Study 17976222 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg po/d, given for 6‐8 days before surgery)
Number of subjects: 35
Study 16629348 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 to 300 mg daily)
Number of subjects: 141
Study 16629348 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 to 40 mg daily)
Number of subjects: 141
Study 16629348 — intervention group
Group type: COMPARATOR
Intervention: Bupropion SR and Paroxetine
Number of subjects: 141
Study 14667956 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dose of rosuvastatin 40 mg
Number of subjects: 10
Study 14667956 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of rosuvastatin 8 mg over 4 hours
Number of subjects: 10
Study 11027740 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (mean daily dose of 412 microg, mean cumulative dose of 1.35 g over 9.2 years)
Number of subjects: 211
Study 11027740 — intervention group
Group type: COMPARATOR
Intervention: Control group (asthma patients who never received inhaled corticosteroids)
Number of subjects: 211
Study 11027740 — intervention group
Group type: COMPARATOR
Intervention: Healthy siblings (serving as controls)
Number of subjects: 211
Study 9203786 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (50 mg/kg per day in four divided doses)
Number of subjects: 48
Study 9203786 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole (10 mg/kg per day of trimethoprim and 50 mg/kg per day of sulphamethoxazole in two divided doses for five days)
Number of subjects: 48
Study 9203786 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic)
Number of subjects: 48
Study 1306084 — intervention group
Group type: EXPERIMENTAL
Intervention: Supro isolated soy protein (1.5 g/kg/day, 8 weeks)
Number of subjects: 66
Study 1306084 — intervention group
Group type: COMPARATOR
Intervention: Control group (no soy protein supply)
Number of subjects: 66
Study 3511977 — intervention group
Group type: EXPERIMENTAL
Intervention: Single administration of E. coli AZ (group A)
Number of subjects: 60
Study 3511977 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple administrations of E. coli AZ (group B)
Number of subjects: 60
Study 3511977 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) receiving no administration
Number of subjects: 60
Study 31884246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 500
Study 31884246 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (placebo)
Number of subjects: 500
Study 29885082 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (RSV) 500 mg 3 times daily for 6 months
Number of subjects: 16
Study 29885082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29885082 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (RSV)
Number of subjects: 16
Study 27622961 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive yoga package (including physical asanas, pranayama, and meditation)
Number of subjects: 200
Study 27622961 — intervention group
Group type: COMPARATOR
Intervention: Routine physical training activities
Number of subjects: 200
Study 24863850 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicompartmental knee arthroplasty (BKA)
Number of subjects: 50
Study 24863850 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 50
Study 21451421 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (100-300 mg once daily)
Number of subjects: 0
Study 21451421 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (75-225 mg once daily)
Number of subjects: 0
Study 17315420 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 22
Study 17315420 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 22
Study 12378634 — intervention group
Group type: COMPARATOR
Intervention: OAM: metronidazole 500 mg bid, amoxicillin 1 g bid, omeprazole 20 mg bid
Number of subjects: 100
Study 12378634 — intervention group
Group type: EXPERIMENTAL
Intervention: OAA: azithromycin 1 g od for the first 3 days, amoxicillin 1 g bid, omeprazole 20 mg bid
Number of subjects: 100
Study 12378634 — intervention group
Group type: COMPARATOR
Intervention: OAM
Number of subjects: 100
Study 12378634 — intervention group
Group type: EXPERIMENTAL
Intervention: OAA
Number of subjects: 100
Study 9569650 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuracy motivation
Number of subjects: 0
Study 9569650 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction instructions
Number of subjects: 0
Study 7985743 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to sporozoite‐infected mosquitoes over the previous 28‐day period
Number of subjects: 1007
Study 7985743 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to more than 10 infective bites during the prior 28‐day period
Number of subjects: 1007
Study 7985743 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment during the highest incidence period
Number of subjects: 1007
Study 2694164 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprevention intervention (specific details not provided)
Number of subjects: 80
Study 2694164 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not mentioned)
Number of subjects: 80
Study 1119765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Number of subjects: 13
Study 1119765 — intervention group
Group type: COMPARATOR
Intervention: Control (no hyaluronidase)
Number of subjects: 13
Study 12492615 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient pharmaceutical counselling with MIDS and medicine reminder card
Number of subjects: 43
Study 12492615 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 30944269 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg/d
Number of subjects: 670
Study 30944269 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1,500 mg/d
Number of subjects: 670
Study 29573529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 29573529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26719221 — intervention group
Group type: EXPERIMENTAL
Intervention: French language semi-quantitative food frequency questionnaire (FFQ)
Number of subjects: 53
Study 26719221 — intervention group
Group type: EXPERIMENTAL
Intervention: French language semi-quantitative food frequency questionnaire (FFQ) pre-dietary record (DR)
Number of subjects: 53
Study 26719221 — intervention group
Group type: EXPERIMENTAL
Intervention: French language semi-quantitative food frequency questionnaire (FFQ) post-dietary record (DR)
Number of subjects: 53
Study 25152476 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery plus surgical ventricular reconstruction
Number of subjects: 267
Study 25152476 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass surgery alone
Number of subjects: 267
Study 25152476 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of myocardial viability
Number of subjects: 267
Study 25152476 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anterior wall or apical scar
Number of subjects: 267
Study 22638922 — intervention group
Group type: EXPERIMENTAL
Intervention: SICS with a conjunctival flap
Number of subjects: 220
Study 22638922 — intervention group
Group type: COMPARATOR
Intervention: SICS without a conjunctival flap
Number of subjects: 220
Study 19855309 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit Training (CT)
Number of subjects: 8
Study 19855309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Exhaustion (PE)
Number of subjects: 8
Study 18823203 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolved agent
Number of subjects: 2
Study 18823203 — intervention group
Group type: COMPARATOR
Intervention: Human participants
Number of subjects: 2
Study 16332231 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐TCP + 0.3 mg/ml rhPDGF‐BB in buffer
Number of subjects: 180
Study 16332231 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐TCP + 1.0 mg/ml rhPDGF‐BB in buffer
Number of subjects: 180